A new trading day began on Friday, with Nuvation Bio Inc (NYSE: NUVB) stock price down -4.85% from the previous day of trading, before settling in for the closing price of $8.45. NUVB’s price has ranged from $1.54 to $9.75 over the past 52 weeks.
A company in the Healthcare sector has dropped its sales by -49.14% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 72.30%. With a float of $239.39 million, this company’s outstanding shares have now reached $341.76 million.
Nuvation Bio Inc (NUVB) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Nuvation Bio Inc is 30.38%, while institutional ownership is 53.85%. The most recent insider transaction that took place on Dec 01 ’25, was worth 1,173,255. In this transaction CHIEF MEDICAL OFFICER of this company sold 150,000 shares at a rate of $7.82, taking the stock ownership to the 18,000 shares. Before that another transaction happened on Dec 01 ’25, when Company’s Officer proposed sale 150,000 for $7.82, making the entire transaction worth $1,173,255.
Nuvation Bio Inc (NUVB) Latest Financial update
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.12 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 60.47% during the next five years compared to -49.14% drop over the previous five years of trading.
Nuvation Bio Inc (NYSE: NUVB) Trading Performance Indicators
Here are Nuvation Bio Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 108.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.64, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.49 in one year’s time.
